Scholarlink

Purpose <p>In sinonasal squamous cell carcinoma (SNSCC), evidence regarding the efficacy of immune checkpoint inhibitors (ICIs) and predictive biomarkers remains limited. Immune-related adverse events (irAEs) have been reported as potential indicators of antitumor response and clinical benefit in multiple malignancies; however, their prognostic significance in SNSCC has not been well defined.</p> Methods <p>We retrospectively analyzed 37 patients with recurrent or metastatic (R/M) SNSCC who received ICIs at two institutions. Clinical outcomes, including objective response rate (ORR), overall survival (OS), and progression-free survival (PFS), were assessed. The association between irAE occurrence and OS was evaluated using both landmark analysis and time-dependent Cox proportional hazards models treating irAE occurrence as a time-varying covariate.</p> Results <p>Among the 37 patients, the ORR was 40.5%, with a median OS of 32.1&#xa0;months and median PFS of 6.6&#xa0;months. Twenty-one patients (56.8%) experienced a total of 25 irAEs. In the 3-month landmark analysis, patients with irAEs had significantly better OS and PFS (<i>P</i> = 0.0009 and 0.0008, respectively). However, in the time-dependent Cox model, irAE occurrence was not significantly associated with OS (hazard ratio 0.98, 95% confidence interval 0.38–2.54, <i>P</i> = 0.9627), likely reflecting the influence of late-onset events and the small cohort size.</p> Conclusions <p>Although irAEs were associated with improved survival in landmark analysis, this association was not confirmed in time-dependent analysis, suggesting a potential influence of immortal time bias. Further prospective studies are warranted.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prognostic impact of immune-related adverse events in recurrent or metastatic sinonasal squamous cell carcinoma treated with immune checkpoint inhibitors

  • 期刊论文

  • 发表日期：

    2026年6月15日

查看全文
  • Takahiro Hongo,
  • Tomomi Manako,
  • Yusuke Watanuki,
  • Takuya Masunaga,
  • Yusuke Hirano,
  • Hirotaka Hara,
  • Hirofumi Omori,
  • Masanobu Sato,
  • Moriyasu Yamauchi,
  • Satoshi Toh,
  • Mioko Matsuo,
  • Muneyuki Masuda

摘要

Purpose

In sinonasal squamous cell carcinoma (SNSCC), evidence regarding the efficacy of immune checkpoint inhibitors (ICIs) and predictive biomarkers remains limited. Immune-related adverse events (irAEs) have been reported as potential indicators of antitumor response and clinical benefit in multiple malignancies; however, their prognostic significance in SNSCC has not been well defined.

Methods

We retrospectively analyzed 37 patients with recurrent or metastatic (R/M) SNSCC who received ICIs at two institutions. Clinical outcomes, including objective response rate (ORR), overall survival (OS), and progression-free survival (PFS), were assessed. The association between irAE occurrence and OS was evaluated using both landmark analysis and time-dependent Cox proportional hazards models treating irAE occurrence as a time-varying covariate.

Results

Among the 37 patients, the ORR was 40.5%, with a median OS of 32.1 months and median PFS of 6.6 months. Twenty-one patients (56.8%) experienced a total of 25 irAEs. In the 3-month landmark analysis, patients with irAEs had significantly better OS and PFS (P = 0.0009 and 0.0008, respectively). However, in the time-dependent Cox model, irAE occurrence was not significantly associated with OS (hazard ratio 0.98, 95% confidence interval 0.38–2.54, P = 0.9627), likely reflecting the influence of late-onset events and the small cohort size.

Conclusions

Although irAEs were associated with improved survival in landmark analysis, this association was not confirmed in time-dependent analysis, suggesting a potential influence of immortal time bias. Further prospective studies are warranted.